We believe

Impel NeuroPharma is the first company to attempt to harness the benefits of delivery to the upper nasal space to improve the therapeutic potential of CNS therapies.

Unlike traditional nasal delivery systems, such as pumps, that predominantly deliver medicine to the lower nasal cavity and suffer from high variability and low overall absorption, our therapies are designed to achieve rapid absorption with consistent and predictable doses.1

liquid pod device diagram
powder POD device diagram

The upper nasal space vasculature is more permeable compared to the lower nasal cavity that is less accommodating to drug delivery uptake. These advantages allow for better consistency in dosing and uptake of drugs, as well as the potential for improved efficacy and faster time to onset of action – meaning patients stand to achieve fast and lasting symptomatic relief.2

References

1 Impel Data on File.
2 Impel Data on File.